Novartis AG (NOVN)-Medical Equipment-Deals and Alliances Profile

Novartis AG (NOVN)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME24864D
  • |
  • Pages: 163
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Novartis AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 11

Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Novartis AG, Medical Equipment, Deal Details 20

Venture Financing 20

Lemonaid Health Raises USD11 Million in Series A Financing 20

Atlas Genetics Raises USD35 Million in Series D Financing 20

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 22

Rox Medical Raises USD40 Million in Series E Financing 24

Cota Raises Funds through Venture Financing 25

Ra Pharma Raises USD58.5 Million in Series B Financing 26

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 26

MyoPowers Medical Raises USD5 Million in Venture Financing 28

Autonomic Technologies Raises USD38 Million in Series D Financing 29

Merganser Biotech Raises USD28 Million in Series A Financing 30

Encore Vision Raises USD1 Million in Venture Financing 31

Atlas Genetics Raises USD20 Million in Series C Financing 31

Transcend Medical Raises USD7.2 Million in Venture Financing 33

BioNano Genomics Raises USD53 Million in Series C Venture Financing 33

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 34

ImaginAb Raises US$21 Million In Series B Venture Financing 36

Transcend Medical Raises US$22 Million In Series C Venture Financing 37

Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 38

Encore Vision Secures USD5 Million in Venture Funding 38

Wavetec Vision Raises US$11 Million In Series D-2 Financing 39

Proteus Digital Health Raises US$63 Million In Series F Financing Round 40

Health XL Raises Funds Through Venture Financing 41

Wavetec Vision Raises US$16.5 Million In Venture Financing 42

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 43

ImaginAb Raises US$12.5 Million In Series A Financing 43

WaveTec Vision Raises US$1.5 Million In Venture Financing 44

Transcend Medical Secures USD16 Million in Series B Venture Funding 45

Autonomic Technologies Secures US$32 Million In Series C Venture Financing 46

Atlas Genetics Raises US$27 Million In Series B Financing 47

Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 49

MyoPowers Medical Secures US$18.9 Million In Series B Financing 50

Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 51

WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 52

Wavetec Vision Raises US$3.5 Million In Venture Financing 53

Private Equity 54

dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 54

Partnerships 55

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 55

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 55

Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 56

IRIDEX Enters Into Licensing Agreement With Alcon 57

OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 58

Propeller Health Enters into Agreement with Novartis Pharma 59

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 59

Novartis Enters into Agreement with Microsoft 60

MedinCell Enters into Agreement with Sandoz International 61

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 62

CorTechs Labs Enters into Agreement with Novartis Pharma 63

Qiagen Enters into Co-Development Agreement with Novartis 63

SomaLogic Extends Co-Development Agreement with Novartis 64

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 65

Foundation Medicine Expands Co-Development Agreement With Novartis 66

Foundation Medicine Extends Co-Development Agreement With Novartis 67

Grifols Enters Into Co-Marketing Agreement With Novartis 67

Foundation Medicine Enters Into An Agreement With Novartis 68

Sunovion Pharma Enters into Licensing Agreement with Novartis 69

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 70

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 70

Life Technologies Enters Into Licensing Agreement With Novartis 71

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 72

Debt Offering 73

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 73

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 73

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 74

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 75

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 76

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 77

Asset Transactions 78

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 78

Novartis Plans to Divest Assets of Alcon 79

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 79

Acquisition 81

GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 81

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 82

Alcon to Acquire Transcend Medical 83

Novartis May Acquire Genfit 84

Novartis Acquires Ziarco Group 85

Novartis Acquires Encore Vision 86

Novartis Plans to Sell its Stake in F. Hoffmann-La Roche 87

Alcon Acquires WaveTec Vision Systems 87

Novartis Acquires Vivacta For US$90 Million 89

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 90

Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 91

Novartis AG-Key Competitors 94

Key Employees 95

Locations And Subsidiaries 97

Head Office 97

Other Locations & Subsidiaries 97

Recent Developments 116

Strategy And Business Planning 116

May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 116

Financial Announcements 118

Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 118

Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 122

Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 128

Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 134

Apr 21, 2016: Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth 140

Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 145

Corporate Communications 153

May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 153

Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 154

Other Significant Developments 155

Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 155

Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 156

Jan 26, 2017: Achievement of sales milestone for COPD products 157

Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 158

Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159

May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 160

May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis 161

Mar 31, 2016: Novartis publishes updated 2015 segment financials reflecting new division structure 162

Appendix 163

Methodology 163

About GlobalData 163

Contact Us 163

Disclaimer 163

List of Figures

Novartis AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Novartis AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Novartis AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 9

Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Novartis AG, Medical Equipment, Deals by Market, 2011 to YTD 2017 11

List of Tables

Novartis AG, Medical Equipment, Key Facts, 2016 1

Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Novartis AG, Deals By Market, 2011 to YTD 2017 11

Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Lemonaid Health Raises USD11 Million in Series A Financing 20

Atlas Genetics Raises USD35 Million in Series D Financing 20

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 22

Rox Medical Raises USD40 Million in Series E Financing 24

Cota Raises Funds through Venture Financing 25

Ra Pharma Raises USD58.5 Million in Series B Financing 26

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 26

MyoPowers Medical Raises USD5 Million in Venture Financing 28

Autonomic Technologies Raises USD38 Million in Series D Financing 29

Merganser Biotech Raises USD28 Million in Series A Financing 30

Encore Vision Raises USD1 Million in Venture Financing 31

Atlas Genetics Raises USD20 Million in Series C Financing 31

Transcend Medical Raises USD7.2 Million in Venture Financing 33

BioNano Genomics Raises USD53 Million in Series C Venture Financing 33

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 34

ImaginAb Raises US$21 Million In Series B Venture Financing 36

Transcend Medical Raises US$22 Million In Series C Venture Financing 37

Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 38

Encore Vision Secures USD5 Million in Venture Funding 38

Wavetec Vision Raises US$11 Million In Series D-2 Financing 39

Proteus Digital Health Raises US$63 Million In Series F Financing Round 40

Health XL Raises Funds Through Venture Financing 41

Wavetec Vision Raises US$16.5 Million In Venture Financing 42

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 43

ImaginAb Raises US$12.5 Million In Series A Financing 43

WaveTec Vision Raises US$1.5 Million In Venture Financing 44

Transcend Medical Secures USD16 Million in Series B Venture Funding 45

Autonomic Technologies Secures US$32 Million In Series C Venture Financing 46

Atlas Genetics Raises US$27 Million In Series B Financing 47

Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 49

MyoPowers Medical Secures US$18.9 Million In Series B Financing 50

Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 51

WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 52

Wavetec Vision Raises US$3.5 Million In Venture Financing 53

dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 54

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 55

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 55

Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 56

IRIDEX Enters Into Licensing Agreement With Alcon 57

OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 58

Propeller Health Enters into Agreement with Novartis Pharma 59

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 59

Novartis Enters into Agreement with Microsoft 60

MedinCell Enters into Agreement with Sandoz International 61

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 62

CorTechs Labs Enters into Agreement with Novartis Pharma 63

Qiagen Enters into Co-Development Agreement with Novartis 63

SomaLogic Extends Co-Development Agreement with Novartis 64

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 65

Foundation Medicine Expands Co-Development Agreement With Novartis 66

Foundation Medicine Extends Co-Development Agreement With Novartis 67

Grifols Enters Into Co-Marketing Agreement With Novartis 67

Foundation Medicine Enters Into An Agreement With Novartis 68

Sunovion Pharma Enters into Licensing Agreement with Novartis 69

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 70

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 70

Life Technologies Enters Into Licensing Agreement With Novartis 71

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 72

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 73

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 73

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 74

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 75

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 76

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 77

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 78

Novartis Plans to Divest Assets of Alcon 79

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 79

GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 81

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 82

Alcon to Acquire Transcend Medical 83

Novartis May Acquire Genfit 84

Novartis Acquires Ziarco Group 85

Novartis Acquires Encore Vision 86

Novartis Plans to Sell its Stake in F. Hoffmann-La Roche 87

Alcon Acquires WaveTec Vision Systems 87

Novartis Acquires Vivacta For US$90 Million 89

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 90

Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 91

Novartis AG, Key Competitors 94

Novartis AG, Key Employees 95

Novartis AG, Subsidiaries 97

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com